EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Aberrant Sialylation to Treat Cancer

Jennifer Munkley iD, Emma Scott iD

Medicines · 13.10.2019 · 6 (4) · 102

DOI: 10.3390/medicines6040102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicines, online erschienen am 13.10.2019. Verfasst von Jennifer Munkley und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics.

Schlagwörter

Stichwörter der Autor:innen

cancerglycansglycosylationimmunotherapysialic acidsialylationtherapeutics

Autor:innen und Institutionen

  • Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.
  • Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK. Emma.Scott@newcastle.ac.uk.

ORCID-Profile: Jennifer Munkley, Emma Scott

Förderung

  • Prostate Cancer UK

Zitieren

APA

Munkley, J., & Scott, E. (2019). Targeting Aberrant Sialylation to Treat Cancer. Medicines, 6(4), 102. https://doi.org/10.3390/medicines6040102

Vancouver

Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines. 2019;6(4):102. doi:10.3390/medicines6040102

BibTeX
@article{Munkley2019,
  author = {Munkley, Jennifer and Scott, Emma},
  title = {Targeting Aberrant Sialylation to Treat Cancer},
  journal = {Medicines},
  year = {2019},
  volume = {6},
  number = {4},
  pages = {102},
  doi = {10.3390/medicines6040102}
}
Kostenlos starten →